Bechtold S.,Ludwig Maximilians University of Munich |
Blaschek A.,Ludwig Maximilians University of Munich |
Raile K.,Medical University of Berlin |
Dost A.,University Hospital Jena |
And 5 more authors.
Diabetes Care | Year: 2014
Objective Type 1 diabetes and multiple sclerosis (MS) are typical autoimmune diseases in children and young adults. We assessed the co-occurrence of type 1 diabetes and MS by estimating the relative risk (RR) for MS in a pediatric and adolescent diabetic population and looked for possible influencing factors. Research Design And Methods Within the Diabetes Patienten Verlaufsdokumentation (DPV)-Wiss Project, from January 1995 to October 2012, data from 56,653 patients with type 1 diabetes were collected in 248 centers in Germany and Austria. Published data on German and Mid-European MS prevalence were taken for comparison. Multivariable regression analysis was used to identify confounders for co-occurrence of type 1 diabetes and MS. Results The RR forMS in patients with type 1 diabetes was estimated at 3.35-4.79 (95% CI 1.56-7.21 and 2.01-11.39, respectively). Immigration status in all patients (P 0.05) and the presence of thyroid antibodies in male patients only (P = 0.05) were identified as influencing factors on MS incidence within the DPV database. The month-of-birth pattern revealed that risk was higher during the spring and summermonths in the populationwith type 1 diabetes and MS in comparisonwith the population with type 1 diabetes. Conclusions The present cohort study demonstrates a higher risk of co-occurrence of MS in a pediatric and adolescent diabetic population. Immigration status and thyroid antibodies in male patients were independent risk indicators for the incidental rate ofMS. Diabetic patients born during spring and summer had a higher risk for the development of MS. We suggest that environmental factors modulate the individual's risk for the co-occurrence of both diseases. © 2014 by the American Diabetes Association.
Frede J.,Imperial College London |
Frede J.,University of Heidelberg |
Fraser S.P.,Imperial College London |
Oskay-Ozcelik G.,Medical University of Berlin |
And 7 more authors.
European Journal of Cancer | Year: 2013
Ovarian cancer is associated with limited overall survival, due to problems in early detection and therapy. Membrane ion channels have been proposed to play a significant, concerted role in the cancer process, from initial proliferation to metastasis, and promise to be early, functional biomarkers. We review the evidence for ion channel and aquaporin expression and functioning in human ovarian cancer cells and tissues. In vitro, K+ channels, mainly voltage-gated, including Ca2+-activated channels, have been found to control the cell cycle, as in other cancers. Voltage-gated, volume-regulated and intracellular Cl- channels have been detected in vitro and in vivo and shown to be involved in proliferation, adhesion and invasion. Evidence for 'transient receptor potential', voltage-gated sodium and calcium channels, which have been shown to contribute to pathogenesis of other carcinomas, is also emerging in ovarian cancer. Aquaporins may be involved in cell growth, migration and formation of ascites via increased water permeability of micro-vessels. It is concluded that functional expression of ion channels and their regulation by steroid hormones and growth factors are an integral part of ovarian cancer development and progression. Furthermore, ion channels may be involved in multidrug resistance, commonly associated with treatment of ovarian cancer. We propose that ion channel studies can facilitate our understanding of the pathobiology of ovarian cancer and, ultimately, can serve as viable novel targets for its clinical management. © 2013 Elsevier Ltd. All rights reserved.
Woopen H.,Medical University of Berlin |
Pietzner K.,Medical University of Berlin |
Darb-Esfahani S.,Charite - Medical University of Berlin |
Oskay-Oezcelik G.,Medical University of Berlin |
Sehouli J.,Medical University of Berlin
Medical Oncology | Year: 2012
Cutaneous metastasation is a very rare manifestation of ovarian cancer. We present the case of a 64-year-old woman with recurrent platinum-refractory ovarian cancer and skin metastasis. The patient was treated with intraperitoneal catumaxomab due to massive refractory malignant ascites. Clinical response of the skin metastasis was observed during the intraperitoneal treatment with catumaxomab. Even though response of extraperitoneal tumor sites can be explained with intravascular uptake and a possible vaccination effect, this phenomenon has not been reported up to this point to the best of our knowledge. © 2012 Springer Science+Business Media, LLC.